Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01LAC
|
|||
| Former ID |
DNC009632
|
|||
| Drug Name |
MOFEGILINE
|
|||
| Synonyms |
Mofegiline; Mofegiline (free base); UNII-1FMJ6D8Y1B; MDL 72974; 119386-96-8; MDL-72,974; 1FMJ6D8Y1B; CHEMBL489079; C11H13F2N; (E)-2-(Fluoromethylene)-4-(p-fluorophenyl)butylamine; Benzenebutanamine, 4-fluoro-beta-(fluoromethylene)-, (E)-; (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine; Mofegiline [INN]; AC1O5OIU; 4-fluoro-beta-(fluoromethylene)benzenebutanamine; SCHEMBL1295041; GTPL9754; VXLBSYHAEKDUSU-JXMROGBWSA-N; ZINC1542534; Mofegiline Hydrochloride (free base); MDL-72974; BDBM50246766; AKOS006271451; LS-172413
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Discontinued in Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13F2N
|
|||
| Canonical SMILES |
C1=CC(=CC=C1CCC(=CF)CN)F
|
|||
| InChI |
1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+
|
|||
| InChIKey |
VXLBSYHAEKDUSU-JXMROGBWSA-N
|
|||
| CAS Number |
CAS 119386-96-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Monoamine oxidase type B (MAO-B) | Target Info | Modulator | [2], [3] |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation via tryptamine | ||||
| Dopamine degradation | ||||
| Putrescine degradation III | ||||
| Noradrenaline and adrenaline degradation | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| Histidine metabolism | ||||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| Tryptophan metabolism | ||||
| Drug metabolism - cytochrome P450 | ||||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Dopaminergic synapse | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| 5-Hydroxytryptamine degredation | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| WikiPathways | Tryptophan metabolism | |||
| Dopamine metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002656) | |||
| REF 2 | Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. J Med Chem. 2008 Dec 25;51(24):8019-26. | |||
| REF 3 | Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial. Clin Pharmacol Ther. 1995 Sep;58(3):342-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.